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Abstract
Background: Systemic sclerosis is a systemic connective tissue disease characterized by endothelium damage,
fibrosis, and subsequent atrophy of the skin. Perioral fibrosis produces a characteristic microstomia together with
microcheilia, both of which cause severe difficulties and affects patients’ daily life, such as eating and oral hygiene.
Since there are no effective and specific therapies, we have aimed at evaluating the response to filler injections of
hyaluronic acid together with platelet-rich plasma.
Methods: Ten female patients aged between 18 and 70 were included in this study. Each patient was treated with
three filler injections of hyaluronic acid and platelet-rich plasma at an interval of 15 to 20 days. Follow-up check-ups
were recorded 1, 3, and 24 months after the end of the treatment. During the therapy and the subsequent follow-
up, we evaluated the mouth’s opening, freedom of movement of the lips, and skin elasticity.
Results: After the treatment, patients had achieved good results already after the first injection and the
improvement was maintained in the following months, up to 2 years. In particular, 8 (80%) patients showed a
greater mouth’s opening and increased upper lip’s thickness during 1-month follow-up and maintained these
results after 2 years (maximum mouth’s opening T0 47.61; T3 49.23; T4 48.60 p < 0.0001. Upper lip’s thickness T0
4.20; T3 4.75; T4 4.45 p < 0.0001). Moreover, distance between upper and lower incisors (T0 27.05; T3 29.03; T4 28.14
p < 0.0001), inter-commissural distance (T0 49.12; T3 51.44; T4 50.31: p < 0.0001), and lower lip’s thickness (T0 3.80; T3
4.85, 5.10; T4 4.25; p < 0.0001) were increased in all of patients in 1-month follow-up, keeping these benefits after
24 months and having a significant increase of skin elasticity 1 month after the end of therapy.
Conclusions: Our study demonstrates that filler injections of hyaluronic acid and platelet-rich plasma represent an
efficient local therapeutic alternative for patients affected by scleroderma. The treatment has significantly improved
patients’ quality of living.
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Background
Systemic sclerosis (SSc) is a systemic connective tissue
disease characterized by endothelium damage, fibrosis,
and subsequent atrophy of the skin, subcutaneous tissue,
muscles, and internal organs (i.e., digestive tract, lungs,
heart, kidney) [1, 2]. Skin fibrosis is prominent and
widespread in diffuse cutaneous SSc (dcSSc), whereas in
limited cutaneous SSc (lcSSc) vascular complications
rather than fibrosis tend to predominate [1]. Fibrotic
skin is characterized by thick dermis and obliteration of
hair follicles, sweat glands, and cutaneous blood vessels.
Initially, fibrosis is most prominent in the reticular der-
mis but the subjacent adipose layer will also progres-
sively be affected. These events are responsible for
modifying facial features, by showing tight skin with loss
of wrinkles and delivering a typical “mask-like” face.
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Moreover mild to severe restriction of mouth opening is
also described [2–4].
Perioral fibrosis produces a characteristic microstomia
together with microcheilia, causing severe difficulties in
different aspects of daily life, such as eating and oral hy-
giene. In the end, due to fibrosis, patients lose their fa-
cial skin feeling [5].
Skin thickening is an important manifestation of sys-
temic sclerosis affecting patients’ life, with only 2% of
patients not reporting this sign.
In consideration of all the above observations, the
treatment of skin fibrosis represents one of the major
goals for these patients. Unfortunately, skin atrophy
therapy remains a main unmet need [3].
Although there are no specific drugs for treatment,
many strategies have been tried (pharmacological or
non-pharmacological treatment) [3–6] such as UVA
phototherapy [7–9], corticosteroids and immunomodula-
tors [10], topical calcitriol [11–13], and etretinate [14–17],
but none of these has given a good and long-lasting result.
Recent findings support injections of hyaluronic acid
(HA), an anionic, non-sulfated glycosaminoglycan distrib-
uted widely throughout connective, epithelial, and neural
tissues as a possible treatment of skin fibrosis [18, 19]. In-
deed, this could be a valid therapy due to its properties of
filling the gaps and softening and moisturizing the skin
being able to bind water [20]. Moreover, studies have
demonstrated that it induces production of type I colla-
gen in the dermis and this could explain its long-lasting
effects [21, 22].
Also, platelet-rich plasma (PRP) [23], a plasma fraction
whose concentration is above the peripheral blood level
able to release various growth factors [24, 25] that en-
hance wound-healing, represents a possible effective treat-
ment for the skin ulcers in SSc patients. In particular,
these growth factors and their role in cell proliferation,
angiogenesis, and inflammation suppression explain PRP
use in this new protocol.
In relation to HA and PRP properties, this study shows
the results derived by the combined HA and PRP as re-
generative treatment for the facial fibrotic skin of SSc
patients.
Material and methods
Patient data
This prospective, open-label, monocentric single-arm
study was conducted in patients with systemic sclerosis
recruited from the Rheumatology Section of Policlinico
“Paolo Giaccone” of Palermo.
In this study, we enrolled 10 patients with SSc diagnosed
according to the 2013 classification criteria for systemic
sclerosis [26–30]. Patient characteristics are described in
Table 1. Modified Rodnan skin score was calculated to as-
sess the extension of skin involvement [31].
This study was approved by the Ethical Committee of
the University Hospital in Palermo, and informed con-
sent was obtained from each patient in accordance with
the Helsinki Declaration.
The study exclusion criteria were as follows: the pres-
ence of infectious disease (i.e., HIV, HBV, HCV), preg-
nancy, lactation, and BMI less than 17 kg/m2.
A-CP HA KIT medical device
A-CP HA Kit is a medical device used for the extempor-
aneous production of a mixture of platelet-rich plasma
and hyaluronic acid with a closed-circuit procedure to
ensure sterility. In this kit, there are three tubes A-CP
HA sterile, apyrogenic, and disposable, individually blis-
tered, to be used in three different sessions.
Each A-CP HA tube is vacuum and contains:
– Two milliliters of HA gel in phosphate buffer,
obtained by fermentation, that it is linear, non-
cross-linked, medium-high molecular weight.
– Two milliliters of inert polyester separator gel. It is a
latest-generation thixotropic gel, covered by an
Table 1 Demographic and clinical characteristics of patients
Gender Age SSc type Disease duration Autoantibodies DMARDs
Patient 1 F 38 Limited 7 ANA, anti-CENP-B MMF, HCQ
Patient 2 F 62 Limited 7 ANA RTX
Patient 3 F 53 Diffuse 4 ANA, anti-Scl70 AZA, HCQ
Patient 4 F 47 Diffuse 8 ANA, anti-Scl70 RTX
Patient 5 F 38 Diffuse 2 ANA, anti-Scl70 AZA
Patient 6 F 45 Diffuse 9 ANA, anti-CENP-B HCQ
Patient 7 F 33 Diffuse 9 ANA MMF
Patient 8 F 51 Diffuse 5 ANA, anti-Scl70 MMF
Patient 9 F 41 Diffuse 2 ANA HCQ
Patient 10 F 40 Diffuse 7 ANA, anti-Scl70 MMF, HCQ
MMF mycophenolate mofetil, HCQ hydroxychloroquine, RTX rituximab, AZA azathioprine
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international license, biocompatible, for clinical use,
which ensures an optimal and standardized cellular
recovery in the PRP and separates these cells from
the waste component, reducing contamination risk
and making the technique non-operator sensitive.
– 0.6 ml of anticoagulant (sodium citrate 4%).
Briefly, the PRP and HA were obtained by mixing 7ml of
blood taken from a peripheral vein and automatically col-
lected in the tubes. Then, the tube was centrifuged at 1500g
for 5min with one-step technique. After the centrifugation,
we obtained about 3ml of PRP—the concentration may be
different from patient to patient in accordance with blood
platelet concentration—with platelet recovery over 80% and
white and red cells depletion over 90% and 99.5% respect-
ively. Later, we rolled the tube horizontally in order to
obtain a homogeneous mixture of PRP and HA without
damaging cells. The final result of this process was a mix-
ture of about 4ml of PRP and HA in the same proportion
(2ml of PRP and 2ml of HA) that was distributed on 1-ml
Luer-Lock syringes with 27-G needle (Fig. 1).
Videodermatoscopy
Before the treatment, skin patients were examined by
videodermatoscopy [32] at the Dermatology Section of
Policlinico “Paolo Giaccone” of Palermo. In particular,
capillaries in the living skin above the left upper lip were
examined, and a surface of 1 cm2 was taken in each
image, applying × 30 and × 150 magnifications, and
using white light and fluorescent light.
Another videodermatoscopy was performed about 30
days after the third injection to seek if any changes had
occurred during the treatment.
Skin Elastometer device
During the first medical examination, skin elasticity of
patients’ face was measured with Skin Elastometer de-
vice. The probe was placed on their left cheek and above
the left upper lip. After placing the probe, the skin was
aspirated for 3 s with a negative pressure of 400 mbar,
and at the end of this time, other 3 s was needed for the
skin to return to its initial position. The value, shown as
a percentage, has to be related to age patient as the elas-
ticity decreases with increasing age. This examination
was also done, in the same way, about 30 days after the
last injection to seek whether any changes occurred dur-
ing the treatment.
Study protocol
Study protocol consists in three injections: each one was
performed 15–20 days after the other. The same day of
the injection, some parameters were examined using
digital electronic caliper (Fig. 2): the maximum mouth’s
opening (measured from the vermillion edge of the
upper lip to the one of the lower lip), the distance be-
tween upper and lower incisors, the inter-commissural
distance (measured from a labial commissure to the
other, along the vermillion edge of the lower lip with oc-
cluded teeth), and the upper and lower lip’s thickness.
Moreover, photos of patients were taken in three dif-
ferent projections—frontal, ¾ right and ¾ left—before
and after each injection.
About 15 min before the injection, anesthetic cream
was used on the patient’s face to reduce pain. When the
mixture of PRP and HA was ready, we gave the injec-
tions in temporal and zygomatic regions, nose-lip junc-
tion, perioral area, lips, and chin. At the end of each
treatment, an antibacterial cream based on gentamicin
was used to prevent infection and an appropriate cream
was used for bruises, when necessary.
Injections were given in the clinic, and they did not cause
side effects except some bruises. At the end of each treat-
ment, patients came back home with no pain or discomfort.
Thus, there was no need to admit or to observe patients.
When the whole treatment ended, patients were vis-
ited again 1, 3, and 24months after the last injections in
Fig. 1 A-CP HA medical device: tube containing 2 ml of HA gel in phosphate buffer, 2 ml of inert polyester separator gel, and 0.6 ml of
anticoagulant (a), tube with 7 ml of blood (b), and tube after centrifugation at 1500 g for 5 min (c)
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order to examine the same parameters: maximum
mouth’s opening, distance between upper and lower in-
cisors, inter-commissural distance, and upper and lower
lip’s thickness. Moreover, photos of patients were taken
in the same three projections: frontal, ¾ right, and ¾ left.
On the same day, skin elasticity and capillaries in the liv-
ing skin were examined as for the first time.
Follow-up ended with an interview with the patients,
to know esthetic and functional benefits gained after the
treatment, as well as any critical issues and their overall
satisfaction about results achieved. Questions about skin
hydration degree and need to apply moisturizers, skin
elasticity and pain with mouth movements were asked.
Statistical analyses
Measurements are expressed as mean ± standard deviation
(DS). To analyze differences between outcomes measured
at different time period, we used both parametric and
non-parametric analysis.
Parametric analysis has been conducted using standard
one-way repeated measures ANOVA with the Greenhouse-
Geisser correction factor to correct for violation of the
sphericity assumption. The latter is tested by using the
Mauchly test.
Non-parametric analysis has been implemented using
the Friedman test. The null hypothesis for the Friedman
test is that there are no differences between the out-
comes measured at different time period. Rejection of
the null-hypothesis indicates that that two or more out-
come’s time-specific measures are significantly different
from each other.
Finally, to investigate whether treatment is persistent,
we also rely on the non-parametric Wilcoxon signed-
rank test which compare mean ranks of each period with
the baseline measured at time 0.
p < 0.05 was considered significant.
Results
Clinical evaluation
Clinical parameters were evaluated at each time point,
and results are summarized in Table 2 and Fig. 3. The
parameters measured during the third injection and dur-
ing follow-up (1 month, 3 months, and 2 years after the
third injection) were compared with the baseline data
(before treatment) and all of them showed a statistically
significant improvement, although it seems to decline
over time. Anybody was lost to follow-up.
Dermoscopic evaluation
Comparing images obtained at baseline and 30 days after
the third injection, we observe that capillary density
remained stable in 100% of patients. Vascular ectasia is
slightly increased in 4 (40%) out of 10 patients, it has
remained stable in 3 (30%) out of 10 patients, and it is
undetectable in 3 (30%) out of 10 patients.
Elastometer evaluation
Comparing measurements obtained before the treatment
and 30 days after its end, we can observe that 100% of
the patients had a significant increase of skin elasticity
(Table 3).
Patient’s evaluation
During the therapy and the subsequent follow-up, we
interviewed patients we wanted to know about the es-
thetic and functional benefits derived after the treat-
ment, as well as any critical issues and their satisfaction
about results achieved. In particular, all of the patients
were satisfied of the improvements. Indeed, in four
(40%) cases, the skin became more hydrated and softer
with less need to apply moisturizers. Lips had the same
outcome. Three (30%) patients have reported increased
skin elasticity. Seven (70%) patients said to have regained
Fig. 2 Parameters examined by digital electronic caliper: maximum mouth’s opening (a), distance between upper and lower incisors (b), and
inter-commissural distance (c)
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the feeling of their own skin and skin sensitivity which
they had lost years before. Moreover, four (40%) patients
could open their mouth and suffered less when doing
this movement. Three (30%) patients said that flushing
and hematoma (potential side effects of injections) de-
creased gradually during the treatment.
Discussion
Systemic sclerosis is a chronic connective tissue inflamma-
tory disease responsible for severe facial skin alterations that
cause limitations and difficulties in different areas of daily
life, as well as disfiguring malformations and changes in ap-
pearance [5]. Additionally, to date, there are no effective
local therapies that can guarantee a satisfactory result nei-
ther from an esthetic nor from a functional point of view
[6–17]. To date, the only therapeutic strategies that achieved
results consisted in autologous fat grafting [33, 34]. In par-
ticular, some studies are concerned with only the treatment
of microstomia using autologous fat grafting with [35] or
without PRP [36]. Moreover, Virzì et al. treated sclerodermic
Fig. 3 Graphs of clinical parameters (maximum mouth’s opening, distance between upper and lower incisors, inter-commissural distance, upper
and lower lip’s thickness) in all patients (each line represents a different patients) for each time point (baseline (T0), during the third injection (T1),
the 1-month follow-up (T2), the 3-month follow-up (T3), and the 24-month follow-up (T4))
Table 2 Clinical parameters (maximum mouth’s opening, distance between upper and lower incisors, inter-commissural distance,
upper and lower lip’s thickness), expressed as mean ± SD at baseline (T0), during the third injection (T1), the 1-month follow-up (T2),
the 3-month follow-up (T3), and the 24-month follow-up (T4)
Baseline (T0) 1 month (T1) 2 months (T2) 3 months (T3) 24 months (T4) Comparison to
the baseline
ANOVA Friedman test
Mean (SD) Mean (SD) Mean (SD) Mean (SD) Mean (SD) p value F p value Test
Stat.
Appr.
p value
T0/T3 T0/T4
Maximum mouth’s
opening (mm)
47.61 (4.56) 50.91 (6.47) 50.35 (6.19) 49.23 (5.27) 48.60 (5.30) 0.0059 0.0093 11.48 0.0015 30.45 < 0.0001
Distance between
upper and lower
incisors (mm)
27.05 (5.80) 30.65 (5.71) 30.41 (5.90) 29.03 (5.65) 28.14 (5.61) 0.0051 0.0069 22.36 < 0.0001 33.04 < 0.0001
Inter-commissural
distance (mm)
49.12 (1.55) 51.54 (3.01) 53.43 (2.79) 51.44 (2.47) 50.31 (2.02) 0.0058 0.0065 23.68 < 0.0001 32.50 < 0.0001
Upper lip’s
thickness (mm)
4.20 (1.54) 5.25 (1.62) 5.65 (1.52) 4.75 (1.35) 4.45 (1.32) 0.0154 0.15 19.64 < 0.0001 29.52 < 0.0001
Lower lip’s
thickness (mm)
3.80 (1.87) 5.10 (2.13) 5.75 (1.87) 4.85 (1.81) 4.25 (1.85) 0.0041 0.0163 22.98 < 0.0001 31.15 < 0.0001
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facial skin lesions by autologous fat grafting and PRP [37]
and Scuderi et al. by a combination of adipose-derived stro-
mal cells (ASCs) in HA solution [38]. Although all of these
therapeutic approaches achieved goods results, they show
some limitations. In fact, this invasive procedure requires
general anesthesia, the use of the operating room, and ob-
servation of the patient for many hours. Moreover, only a
rate of grafted fat is able to survive depending on several fac-
tors that cannot be quantified. By contrast, HA and PRP are
produced with a closed-circuit procedure to ensure sterility,
injections are given in the clinic, and there is no need to
admit or to observe patients after the treatment. Therefore,
as far as we know, this study attempted to demonstrate, for
the first time, the effectiveness of local intradermal infiltra-
tions of HA and PRP together in the treatment of facial skin
fibrosis of SSc patients. Indeed, in other studies, hyaluronic
acid has been used as a dermal filler in the treatment of a
particular clinical variant of localized scleroderma, the so-
called en coupe de saber [20, 21, 38, 39], but there are no ev-
idences on the use of platelet-rich plasma when treating this
disease.
Therefore, considering HA and PRP properties and their
wide and valid use as filler in the treatment of skin lesions
of several origin [22, 39–42], in this study, we used HA
and PRP infiltrations to treat local facial scleroderma. In-
deed, studies have demonstrated that hyaluronic acid fills
the gaps and softens and moisturizes the skin for its cap-
acity to bind water [20]. Moreover, it induces production
of type I collagen in the dermis, and this could explain its
long-lasting effects [21, 22]. Instead, platelet-rich plasma is
rich in growth factors that are involved in cell prolifera-
tion, angiogenesis, and inflammation suppression that ex-
plain PRP use in this study [23–25]. On these bases, our
study showed the results derived by their combining as
regenerative treatment for the facial fibrotic skin of SSc
patients. In fact, the infiltration had allowed to improve
not only the esthetic appearance, but also the functional
state of the face of the patients, who were able to enjoy re-
elastic skin, increased the mouth opening and no limit lip
movement, as well as recovering the perception of having
the skin on the face. All of this has significantly improved
their life quality as they resumed naturally gestures and
activities commonly considered automatic and gained
more confidence. Our results testify that this treatment
gave clinical and functional benefits and this outcome has
remained stable over time: improvements achieved were
maintained after the end of the treatment although de-
creased gradually during the following 24 months.
In fact, results have also demonstrated a long retention
rate since 60% of patients showed a greater mouth’s
opening and increased upper lip thickness and 80% of
them showed increased distance between upper and
lower incisors, inter-commissural distance, and lower lip
thickness up to 2 years later (nobody was lost to follow-
up). However, this therapy has limitation as its effect is
not permanent [43], but it inevitably requires further in-
filtrations over time. In fact, although the persistence of
the benefit effects lasted after 2 years, results steadily de-
creased, thus requiring ongoing injections to maintain
the outcome, in accordance with other studies [20, 37].
Moreover, our study’s sample consisted of only 10 pa-
tients, and consequently, it would be necessary to in-
crease the sample in order to confirm our results and to
introduce this protocol as a new therapy.
Conclusions
Finally, this study has shown the efficacy of hyaluronic
acid and platelet-rich plasma infiltrations in the treat-
ment of facial skin lesions in SSc patients. In fact, it has
guaranteed a satisfactory result both from an esthetic
and a functional point of view, not only visually but also
instrumentally observed.
These treatments could be considered as a starting
point of a regenerative therapy in SSc patients even if
the small sample size will require to confirm our results
in a largest cohort of patients.
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